PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

Print Friendly, PDF & Email

CONCERNING PATEIENTS WITH MITOCHONDRIAL EPILEPSY: SOUTH PLAINFIELD, N.J., Oct. 26, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease. It is […]